Andhra Pradesh government to launch India's first integrated Precision Oncology ecosystem

The Government of Andhra Pradesh has signed a Memorandum of Understanding (MoU) with AstraZeneca India to launch India's first integrated Precision Oncology ecosystem, bringing together Artificial Intelligence (AI), Next Generation Sequencing (NGS), advanced genomics and the innovation capabilities of Amaravati Quantum Valley (AQV) to transform cancer care.

The collaboration aims to establish a comprehensive technology-enabled model that spans the entire patient journey—from early screening and diagnosis to genomic testing, personalised treatment and long-term follow-up—setting a new benchmark for public healthcare innovation and positioning Andhra Pradesh at the forefront of precision medicine in India.

Bringing together AstraZeneca's global leadership in oncology, the AI and advanced computing ecosystem of Amaravati Quantum Valley, and Andhra Pradesh's vision of technology-enabled healthcare, the collaboration will create an end-to-end precision oncology platform that supports every stage of cancer care—from AI-enabled screening and diagnosis to biomarker testing, treatment planning and long-term follow-up.

As part of the collaboration, AstraZeneca India will facilitate the deployment of Qure.ai's Artificial Intelligence-powered chest X-ray solution across selected government healthcare facilities to strengthen the early detection of lung cancer.

A key pillar of the partnership is the establishment of the Integrated Genomic Solutions Centre (IGSC), a first-of-its-kind initiative in Andhra Pradesh that will significantly expand access to advanced genomic diagnostics for cancer patients. The IGSC will perform Next Generation Sequencing (NGS)-based biomarker testing for lung and breast cancer patients.